Armando Anido
Chairman of the Board and Chief Executive Officer

Armando Anido has served as our Chairman and Chief Executive Officer (CEO) since October 2014. Mr. Anido has more than 30 years of executive, operational and commercial leadership experience in the biopharmaceutical industry, particularly in leading CNS transdermal patch and gel products through the entire product life cycle. Prior to Zynerba, Mr. Anido served as CEO of two publicly traded companies. Most recently, he was the CEO of NuPathe (Nasdaq: PATH), which was acquired by Teva Pharmaceuticals in February 2014. At NuPathe, he led the company through FDA approval of its lead product, Zecuity®, the first transdermal patch for migraine, to pre-launch before successfully selling the company to Teva. He also served as President and CEO of Auxilium Pharmaceuticals (Nasdaq: AUXL), where under his leadership, sales grew from $42 million in 2005 to more than $260 million in 2011 and market capitalization increased from $200 million to more than $900 million. Prior to Auxilium, Mr. Anido served as Executive Vice President, Sales and Marketing, at MedImmune and prior to that, in senior sales and marketing positions at GlaxoWellcome and Lederle Laboratories. At GlaxoWellcome, he was Vice President, Central Nervous System Marketing, responsible for the commercialization of the epilepsy, migraine and depression businesses in the U.S. Mr. Anido currently serves as a director of Altamira Therapeutics (formerly Auris Medical), a pharmaceutical company, and has held such position since April 2016, and as a director of Scynexis, Inc. a pharmaceutical company, and has held such position since January 2019. He formerly served as a director of Aviragen Therapeutics, a pharmaceutical company, from October 2015 to March 2018, Respira Therapeutics, Inc., a pharmaceutical company, from May 2012 through September 2014, and Adolor Corporation, a pharmaceutical company, from September 2003 through December 2011. Mr. Anido earned a BS in Pharmacy and an MBA from West Virginia University.


Terri B. Sebree

Terri B. Sebree has served as our President since October 2014. Ms. Sebree has more than 35 years of executive, development and operational experience in the biopharmaceutical industry, particularly in CNS product development. She has completed more than 10 regulatory submissions and approvals of new pharmaceutical products, including transdermal patch and gel products. Prior to Zynerba, Ms. Sebree co-founded and served as President of NuPathe (Nasdaq: PATH), which was acquired by Teva Pharmaceuticals in February 2014. At NuPathe, she successfully led the effort to develop, achieve regulatory approval, and complete manufacturing of the company’s lead product, Zecuity, the first transdermal patch for migraine. Before founding NuPathe in 2005, Ms. Sebree served as Senior Vice President, Development of Auxilium Pharmaceuticals (Nasdaq: AUXL), where she led the Testim® gel development and approval program. Previously, Ms. Sebree served as Executive Vice President, US Operations at Omnicare (NYSE: OCR). Prior to that, Ms. Sebree served in a variety of management roles with Abbott Laboratories for more than nine years. Ms. Sebree currently serves on the board of directors of Serodus ASA, a private Scandinavian pharmaceutical company. Ms. Sebree holds a BS from Texas A&M University.


Joe Apostolico
Vice President, Human Resources

Joe Apostolico joined Zynerba in March 2018 as Vice President, Human Resources with accountability for all human resources and recruiting initiatives. Joe brings over 30 years of broad global healthcare and pharmaceutical human resources leadership experience to Zynerba, with demonstrated success in scaling life science organizations reflected by measurable successful business results. He most recently served Adaptimmune Therapeutics as Vice President and Global Director, Human Resources. Prior, he spent 28 years with GSK in roles of increasing responsibility, culminating in his tenure as Vice President, Human Resources, Pharmaceutical research and development where he led HR decision-making across GSK’s global R&D organization. Among other initiatives, he established a global early talent program that included a future leadership program for biologists, chemists and physicians, and a fellowship program for clinicians. Immediately prior, he served GSK as Vice President, Human Resources, Medicines Discovery and Development. Mr. Apostolico has a Master of Management degree from Pennsylvania State University, and a Bachelor’s Degree in Commerce and Engineering from Drexel University.


Jim Fickenscher
Chief Financial Officer, Vice President, Corporate Development

James E. Fickenscher has served as our chief financial officer, vice president corporate development since September 2016. Mr. Fickenscher has more than 35 years of financial, business development and executive leadership experience in the pharmaceutical industry. Prior to joining our Company, he served as the senior vice president, chief financial officer of Antares Pharma, Inc., a specialty pharmaceutical company, from November 2014 to September 2016. Previously, Mr. Fickenscher served as chief financial officer of Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, from May 2005 until August 2014. From January 2000 until April 2004, Mr. Fickenscher served as senior vice president chief financial officer of Aventis Behring L.L.C., a wholly owned subsidiary of Aventis, predecessor to Sanofi S.A. Mr. Fickenscher joined Aventis Behring L.L.C. in 1995 as vice president, business development and strategic planning and, from that time until 2000, also held the positions of general manager, Japan and vice president & general manager, Hemophilia Business Unit. Throughout his tenure at Aventis Behring L.L.C, he was also responsible for strategic planning. Prior to Aventis Behring L.L.C., Mr. Fickenscher worked at Rhone-Poulenc Rorer, predecessor to Sanofi S.A., in its Collegeville, PA and Paris, France offices and at Deloitte & Touche LLP.


Terry Hurst
General Manager, Zynerba Pharmaceuticals Pty Ltd (Australia)

Terry Hurst has served as the General Manager of Zynerba Pharmaceuticals Pty Ltd (Australia) since October 2017. He has 16 years of executive management experience in the early phase clinical trial sector of the biopharmaceutical industry. Mr Hurst has extensive experience in General Management in both industry and academia with a focus on clinical research. He has in-depth knowledge of the Australian clinical trial sector having overseen the acquisition and execution of approximately 400 early phase clinical trials. Prior to joining Zynerba, he served as Chief Executive Officer of Q-Pharm Pty Limited, an Australian privately held Early Phase Clinical Trial facility in Brisbane, Queensland. At Q-Pharm, he was responsible for the implementation of strategic initiatives of the Board, and specialised in the management of corporate and business development. Mr. Hurst holds a Bachelor of Science degree from The University of Queensland, Brisbane, Australia, and has completed the General Managers Program at the Australian Graduate School of Management.


Paul Kirsch
Vice President, Regulatory Affairs and Quality Assurance

Paul Kirsch joined Zynerba in January 2020 as Vice President of Regulatory Affairs and Quality Assurance. He brings 30 years of leadership experience in regulatory affairs and registration activities to Zynerba, including interactions with the U.S. Food and Drug Administration, U.S. and international regulatory affairs, labeling, and promotional review. He has led five successful new Drug Applications (NDA) in multiple indications, including orphan and neurology indications. He most recently served Trevena, Inc. as Vice President, Regulatory Affairs where he led the preparation and submission of the company’s first NDA. Prior, he spent over four years with Iroko Pharmaceuticals, culminating in his time as Vice President of Regulatory Affairs where he developed global regulatory strategies for all marketed and investigational products, and served as FDA liaison and regulatory lead for Zorvolex® (diclofenac), Vivlodex® (meloxicam), and Tivorbex® (indomethacin). Mr. Kirsch previously spent nearly 19 years with TEVA / Cephalon, culminating in his tenure as Sr. Director and Group Leader, Regulatory Affairs. There, he successfully led the NDAs for Provigil® (modafinil) and Nuvigil® (armodafinil) through approval and commercialization. Mr. Kirsch began his career with Wyeth-Ayerst Research in Clinical Data Management. He received his Bachelor of Science degree in Biology from the University of Scranton.


Ray Mannion
Vice President, Manufacturing

Ray Mannion has served as our Vice President of Manufacturing since April 2017. Mr. Mannion has more than 35 years of international manufacturing, operations and engineering experience in the pharmaceutical, medical devices and electrical connection systems industries. Prior to Zynerba, he was Senior Director, Third Party Operations for Teva Pharmaceuticals Inc. (NYSE: TEVA) where he successfully managed the production scale up for the commercial launch of the Zecuity® migraine patch while also managing all technical aspects of the project. In addition to his activities with Zecuity, he led a Supplier Relations Team where he collaborated with Teva stakeholders in managing a portfolio of key strategic suppliers in the areas of contract negotiations, product supply, new product launches and product serialization. Prior to Teva, Mr. Mannion held the position of Vice President of Commercial Manufacturing at NuPathe (Nasdaq: PATH) where he led the production scale up and process validation efforts for the Zecuity migraine patch. Prior to NuPathe, Mr. Mannion served as the Vice President of Operations for PuriCore, Inc., where he managed internal and external manufacturing, engineering, quality assurance & regulatory affairs, supply chain, customer service and field service for PuriCore’s US and UK operations. In addition, Mr. Mannion has held various Operations, Engineering and Manufacturing roles with Animas Corporation, Kensey Nash Corporation and AMP Incorporated. Mr. Mannion received a B.S. in Industrial Engineering from Rutgers University, New Brunswick, NJ and an M.B.A from Shippensburg University, Shippensburg, PA.


Carol O’Neill
Vice President, Development

Carol O’Neill has served as our Vice President, Development since October 2014. She has more than 18 years of development and operational experience in the biopharmaceutical industry. Ms. O’Neill has completed regulatory submissions and achieved approvals of new pharmaceutical products including a transdermal patch and a transdermal gel. Prior to joining Zynerba, she served as Vice President, Development Operations of NuPathe (Nasdaq: PATH), which was acquired by Teva Pharmaceuticals in February 2014. At NuPathe, she successfully managed the research and development aspects of the clinical and nonclinical programs of the company’s lead product, Zecuity, the first transdermal patch for migraine. Previously, she was Senior Director Clinical Operations at Auxilium Pharmaceuticals (Nasdaq: AUXL) and Senior Director of Operations analysis at Omnicare Clinical Research (NYSE: OCR). Ms. O’Neill holds a Business Administration degree from Lakehead University, Ontario, Canada.

Stephen O’Quinn, PharmD
Vice President, Medical Affairs

Stephen O’Quinn, Pharm.D. was appointed in November 2021 as our Vice President Medical Affairs. Dr. O’Quinn is a senior pharmaceutical executive with more than 30 years of experience in clinical development, medical affairs and commercialization of medicines in multiple therapy areas, including neurology and psychiatry. Dr. O’Quinn spent over 20 years with GlaxoSmithKline in senior leadership roles.  He most recently served as a consultant to pharmaceutical clients, including Zynerba Pharmaceuticals, supporting clinical development and medical affairs activities.  Dr. O’Quinn earned a Doctor of Pharmacy, with highest honors, from the University of North Carolina at Chapel Hill. He completed a post-doctoral fellowship in Cardiovascular Pharmacotherapy with the UNC School of Pharmacy and Division of Cardiology. He also completed marketing and executive leadership training at The Wharton School of the University of Pennsylvania.


Albert P. Parker
Chief Legal Officer

Al Parker serves as our Chief Legal Officer, joining Zynerba in February 2022. Mr. Parker is an accomplished business and legal executive with more than 25 years of experience in highly regulated industries, including pharmaceuticals, biotech, and medical diagnostics. He has developed deep operating and legal expertise in various C-suite roles for publicly traded healthcare companies and has a proven track record of successfully managing corporate operations and leading legal and compliance teams on a global scale. Prior to Zynerba, Mr. Parker served as Chief Operating Officer and Corporate Secretary for Oncocyte Corporation, a Nasdaq-listed molecular diagnostics company where he led significant M&A and other transactions and had overall P&L responsibility for corporate and lab operations and G&A departments including Legal, HR, IT, and Facilities. Additional roles over the course of his career include Executive VP, General Counsel and Corporate Secretary for Sunovion, a multinational pharma company, and as Senior VP & Global Chief Counsel for Wyeth, a Fortune 100 biopharmaceutical company. A former partner at an AmLaw 250 law firm and founder of a healthcare boutique, Mr. Parker received his JD from the University of Pennsylvania Law School, and his BA in Economics from Penn State University.


Brian Rosenberger
Vice President, Commercial and Business Development

Brian Rosenberger serves as Zynerba’s Vice President, Commercial and Business Development. Over his 25-year career in the pharmaceutical industry, Mr. Rosenberger has held several leadership roles in marketing, sales, business development, analytics and alliance management. Prior to Zynerba, he was Vice President, Alliance & Strategic Portfolio Management of Cipher Pharmaceuticals, a publicly-traded, Canadian-based dermatology company, where he managed the Company’s global portfolio. Mr. Rosenberger also held various roles of increasing responsibility at Auxilium, a specialty biopharmaceutical company. In his last role as Executive Director, Corporate Development & Licensing and Alliance Management, he participated in several transformational M&A, licensing and co-promotion deals through and including Endo International’s acquisition of Auxilium Pharmaceuticals (Nasdaq: AUXL) in January 2015. Mr. Rosenberger held sales managerial positions at Neurocrine Biosciences during the initial commercial build-out of the organization and spent over a decade at GlaxoSmithKline in various US and Global commercial roles within specialty markets, including NeuroHealth Epilepsy Marketing. Mr. Rosenberger received a B.A. double major in Political Science/Policy and Management Studies from Dickinson College in Carlisle, PA.


Nancy Tich, PhD
Vice President, Clinical

Nancy Tich, PhD, serves as Zynerba’s Vice President, Clinical. She has more than 26 years of clinical project management in the biopharmaceutical industry. Prior to joining Zynerba, she served as Senior Director, Project Management, Oncology, at Covance (NYSE: CVD), which was acquired by LabCorp in November 2014. At Covance, she successfully managed numerous oncology clinical projects across various stages of development. Previously, she was Vice President, Client Project Management at Omnicare (NYSE: OCR) and Senior Client Project Manager at Abbott Labs (NYSE:ABT). Dr. Tich earned a Doctorate in Cell Physiology from University of Minnesota and a Bachelor of Arts from Northwestern University.


You are now leaving the Zynerba website

You are being redirected to a third-party website. The terms and conditions of this third-party website may be different from and will govern your use of such website.

Continue (5) Cancel